Jordan vs North Macedonia: Statin use vs. average non-HDL cholesterol levels
Jordan
3.6
in 2018
North Macedonia
3.6
in 2018
Jordan rank
30th
North Macedonia rank
30th
Statin use vs. average non-HDL cholesterol levels over time
- Jordan
- North Macedonia
How they compare
Jordan currently reports 3.6 against 3.6 in North Macedonia, a difference of 0.
Across all 39 years both countries report, North Macedonia has been ahead every year.
Jordan ranks 30th and North Macedonia ranks 30th of 191 countries.
North Macedonia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Jordan | North Macedonia | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.75 | 4.2 | 0.45 | North Macedonia |
| 1990s | 3.98 | 4.1 | 0.12 | North Macedonia |
| 2000s | 3.89 | 3.9 | 0.01 | North Macedonia |
| 2010s | 3.69 | 3.71 | 0.0222 | North Macedonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Jordan or North Macedonia?
- Jordan, at 3.6 against 3.6 in North Macedonia as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Jordan and North Macedonia?
- 0, with Jordan ahead.
- How many years of comparable data are there for Jordan and North Macedonia?
- 39 years are reported by both, from 1980 to 2018.
- How do Jordan and North Macedonia rank globally for statin use vs. average non-hdl cholesterol levels?
- Jordan ranks 30th and North Macedonia ranks 30th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.